Physician profile
John E Dixon
NPI 1407806730
$954.11
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $66.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $181.04 | 2019 | |
| Amgen INC. | $142.02 | 2019 | |
| Merck Sharp & Dohme LLC | $125.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $78.41 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.50 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $69.36 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $62.43 | 2019 | |
| Glaxosmithkline, LLC. | $43.81 | 2019 | |
| Lilly USA, LLC | $37.96 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $34.73 | 2019 | |
| Sanofi Pasteur INC. | $31.21 | 2019-2020 | |
| Allergan, INC. | $29.83 | 2019 | |
| Abbvie INC. | $15.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.65 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.